ID: ALA5183303

Max Phase: Preclinical

Molecular Formula: C21H21N5O5S

Molecular Weight: 455.50

Associated Items:

Representations

Canonical SMILES:  CCOc1cccnc1Oc1cncc(-c2ncc(C(=O)NC3CCS(=O)(=O)C3)cn2)c1

Standard InChI:  InChI=1S/C21H21N5O5S/c1-2-30-18-4-3-6-23-21(18)31-17-8-14(9-22-12-17)19-24-10-15(11-25-19)20(27)26-16-5-7-32(28,29)13-16/h3-4,6,8-12,16H,2,5,7,13H2,1H3,(H,26,27)

Standard InChI Key:  YCVMSJOECUPLAC-UHFFFAOYSA-N

Associated Targets(Human)

Diacylglycerol O-acyltransferase 2 347 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 455.50Molecular Weight (Monoisotopic): 455.1263AlogP: 2.04#Rotatable Bonds: 7
Polar Surface Area: 133.26Molecular Species: NEUTRALHBA: 9HBD: 1
#RO5 Violations: 0HBA (Lipinski): 10HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 13.17CX Basic pKa: 3.23CX LogP: 0.03CX LogD: 0.03
Aromatic Rings: 3Heavy Atoms: 32QED Weighted: 0.57Np Likeness Score: -1.91

References

1. Futatsugi K, Cabral S, Kung DW, Huard K, Lee E, Boehm M, Bauman J, Clark RW, Coffey SB, Crowley C, Dechert-Schmitt AM, Dowling MS, Dullea R, Gosset JR, Kalgutkar AS, Kou K, Li Q, Lian Y, Loria PM, Londregan AT, Niosi M, Orozco C, Pettersen JC, Pfefferkorn JA, Polivkova J, Ross TT, Sharma R, Stock IA, Tesz G, Wisniewska H, Goodwin B, Price DA..  (2022)  Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis.,  65  (22.0): [PMID:36322383] [10.1021/acs.jmedchem.2c01200]

Source